BMC Genomic Data

Table 3 Associations between PTPRO methylation and clinicopathological features of breast cancer

From: Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients

Characteristics	No.	*PTPRO*methylation
		Tumor tissue (%)	χ²	Pvalue	plasma (%)	χ²	Pvalue
Total	98	53 (54)			33 (34)
Age
< 45 years	45	22 (49)			16 (36)
≥ 45 years	53	31 (59)	0.903	0.417	17 (32)	0.132	0.716
Nodal involvement
Negative	61	27 (44)			18 (30)
Positive	37	26 (70)	6.273	0.014	15 (40)	0.935	0.334
Stage
I/II	79	37 (47)			24 (30)
III	19	16 (84)	8.616	0.004	9 (47)	1.979	0.159
Histological type
Non-ductal	23	12 (52)			7 (30)
Ductal	75	41 (55)	1.000	0.510	26 (35)	0.141	0.707
Tumour size
≤20 mm	47	26 (55)			12 (26)
>20 mm	51	27 (53)	0.056	0.842	21 (40)	2.234	0.135
Histological grade
Well/mod diff.	60	27 (45)			18 (30)
Poorly diff.	38	26 (68)	5.139	0.037	15 (40)	0.935	0.334
ER status
Negative	24	16 (67)			10 (42)
Positive	74	37 (50)	2.027	0.167	23 (31)	0.909	0.340
PR status
Negative	29	20 (69)			10 (35)
Positive	69	33 (48)	3.674	0.076	23 (33)	0.012	0.912
HER2 status
Normal	51	19 (37)			12 (24)
Amplified	47	34 (72)	12.124	0.001	21 (46)	5.570	0.018
TP53 status
Normal	59	30 (51)			17 (29)
Mutant	39	23 (59)	0.624	0.535	16 (41)	1.568	0.211

Back to article page

ISSN: 2730-6844

Contact us

General enquiries: journalsubmissions@springernature.com